How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent
During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have cede...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Myles W. Jackson [verfasserIn] |
|---|
| Format: |
Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Perspectives on science - Cambridge, Mass. : MIT Press, 1993, 23(2015), 1, Seite 80-105 |
|---|---|
| Übergeordnetes Werk: |
volume:23 ; year:2015 ; number:1 ; pages:80-105 |
| Links: |
|---|
| DOI / URN: |
10.1162/POSC_a_00160 |
|---|
| Katalog-ID: |
OLC1959670220 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1959670220 | ||
| 003 | DE-627 | ||
| 005 | 20230714151817.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1162/POSC_a_00160 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1959670220 | ||
| 035 | |a (DE-599)GBVOLC1959670220 | ||
| 035 | |a (PRQ)c1211-4f8500efa0b228c425be5ea5eb45317943fc8a525f9f40617bac59f5b757a2d20 | ||
| 035 | |a (KEY)0227781620150000023000100080howgenepatentsarechallengingintellectualpropertyla | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 050 |q ZDB |
| 100 | 0 | |a Myles W. Jackson |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market. | ||
| 650 | 4 | |a Genetic research | |
| 650 | 4 | |a Management | |
| 650 | 4 | |a Intellectual property | |
| 650 | 4 | |a Intellectual property law | |
| 773 | 0 | 8 | |i Enthalten in |t Perspectives on science |d Cambridge, Mass. : MIT Press, 1993 |g 23(2015), 1, Seite 80-105 |w (DE-627)171174844 |w (DE-600)1161190-X |w (DE-576)046617116 |x 1063-6145 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2015 |g number:1 |g pages:80-105 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1162/POSC_a_00160 |3 Volltext |
| 856 | 4 | 2 | |u http://www.mitpressjournals.org/doi/abs/10.1162/POSC_a_00160 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHI | ||
| 912 | |a SSG-OLC-TGE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-BBI | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_179 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_4027 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4193 | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2015 |e 1 |h 80-105 | ||
| author_variant |
m w j mwj |
|---|---|
| matchkey_str |
article:10636145:2015----::ognptnsrcalnignelculrpryateitr |
| hierarchy_sort_str |
2015 |
| publishDate |
2015 |
| allfields |
10.1162/POSC_a_00160 doi PQ20160617 (DE-627)OLC1959670220 (DE-599)GBVOLC1959670220 (PRQ)c1211-4f8500efa0b228c425be5ea5eb45317943fc8a525f9f40617bac59f5b757a2d20 (KEY)0227781620150000023000100080howgenepatentsarechallengingintellectualpropertyla DE-627 ger DE-627 rakwb eng 050 ZDB Myles W. Jackson verfasserin aut How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent 2015 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market. Genetic research Management Intellectual property Intellectual property law Enthalten in Perspectives on science Cambridge, Mass. : MIT Press, 1993 23(2015), 1, Seite 80-105 (DE-627)171174844 (DE-600)1161190-X (DE-576)046617116 1063-6145 nnns volume:23 year:2015 number:1 pages:80-105 http://dx.doi.org/10.1162/POSC_a_00160 Volltext http://www.mitpressjournals.org/doi/abs/10.1162/POSC_a_00160 GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHI SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-BBI GBV_ILN_11 GBV_ILN_40 GBV_ILN_105 GBV_ILN_179 GBV_ILN_702 GBV_ILN_2006 GBV_ILN_4027 GBV_ILN_4125 GBV_ILN_4193 AR 23 2015 1 80-105 |
| spelling |
10.1162/POSC_a_00160 doi PQ20160617 (DE-627)OLC1959670220 (DE-599)GBVOLC1959670220 (PRQ)c1211-4f8500efa0b228c425be5ea5eb45317943fc8a525f9f40617bac59f5b757a2d20 (KEY)0227781620150000023000100080howgenepatentsarechallengingintellectualpropertyla DE-627 ger DE-627 rakwb eng 050 ZDB Myles W. Jackson verfasserin aut How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent 2015 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market. Genetic research Management Intellectual property Intellectual property law Enthalten in Perspectives on science Cambridge, Mass. : MIT Press, 1993 23(2015), 1, Seite 80-105 (DE-627)171174844 (DE-600)1161190-X (DE-576)046617116 1063-6145 nnns volume:23 year:2015 number:1 pages:80-105 http://dx.doi.org/10.1162/POSC_a_00160 Volltext http://www.mitpressjournals.org/doi/abs/10.1162/POSC_a_00160 GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHI SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-BBI GBV_ILN_11 GBV_ILN_40 GBV_ILN_105 GBV_ILN_179 GBV_ILN_702 GBV_ILN_2006 GBV_ILN_4027 GBV_ILN_4125 GBV_ILN_4193 AR 23 2015 1 80-105 |
| allfields_unstemmed |
10.1162/POSC_a_00160 doi PQ20160617 (DE-627)OLC1959670220 (DE-599)GBVOLC1959670220 (PRQ)c1211-4f8500efa0b228c425be5ea5eb45317943fc8a525f9f40617bac59f5b757a2d20 (KEY)0227781620150000023000100080howgenepatentsarechallengingintellectualpropertyla DE-627 ger DE-627 rakwb eng 050 ZDB Myles W. Jackson verfasserin aut How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent 2015 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market. Genetic research Management Intellectual property Intellectual property law Enthalten in Perspectives on science Cambridge, Mass. : MIT Press, 1993 23(2015), 1, Seite 80-105 (DE-627)171174844 (DE-600)1161190-X (DE-576)046617116 1063-6145 nnns volume:23 year:2015 number:1 pages:80-105 http://dx.doi.org/10.1162/POSC_a_00160 Volltext http://www.mitpressjournals.org/doi/abs/10.1162/POSC_a_00160 GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHI SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-BBI GBV_ILN_11 GBV_ILN_40 GBV_ILN_105 GBV_ILN_179 GBV_ILN_702 GBV_ILN_2006 GBV_ILN_4027 GBV_ILN_4125 GBV_ILN_4193 AR 23 2015 1 80-105 |
| allfieldsGer |
10.1162/POSC_a_00160 doi PQ20160617 (DE-627)OLC1959670220 (DE-599)GBVOLC1959670220 (PRQ)c1211-4f8500efa0b228c425be5ea5eb45317943fc8a525f9f40617bac59f5b757a2d20 (KEY)0227781620150000023000100080howgenepatentsarechallengingintellectualpropertyla DE-627 ger DE-627 rakwb eng 050 ZDB Myles W. Jackson verfasserin aut How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent 2015 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market. Genetic research Management Intellectual property Intellectual property law Enthalten in Perspectives on science Cambridge, Mass. : MIT Press, 1993 23(2015), 1, Seite 80-105 (DE-627)171174844 (DE-600)1161190-X (DE-576)046617116 1063-6145 nnns volume:23 year:2015 number:1 pages:80-105 http://dx.doi.org/10.1162/POSC_a_00160 Volltext http://www.mitpressjournals.org/doi/abs/10.1162/POSC_a_00160 GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHI SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-BBI GBV_ILN_11 GBV_ILN_40 GBV_ILN_105 GBV_ILN_179 GBV_ILN_702 GBV_ILN_2006 GBV_ILN_4027 GBV_ILN_4125 GBV_ILN_4193 AR 23 2015 1 80-105 |
| allfieldsSound |
10.1162/POSC_a_00160 doi PQ20160617 (DE-627)OLC1959670220 (DE-599)GBVOLC1959670220 (PRQ)c1211-4f8500efa0b228c425be5ea5eb45317943fc8a525f9f40617bac59f5b757a2d20 (KEY)0227781620150000023000100080howgenepatentsarechallengingintellectualpropertyla DE-627 ger DE-627 rakwb eng 050 ZDB Myles W. Jackson verfasserin aut How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent 2015 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market. Genetic research Management Intellectual property Intellectual property law Enthalten in Perspectives on science Cambridge, Mass. : MIT Press, 1993 23(2015), 1, Seite 80-105 (DE-627)171174844 (DE-600)1161190-X (DE-576)046617116 1063-6145 nnns volume:23 year:2015 number:1 pages:80-105 http://dx.doi.org/10.1162/POSC_a_00160 Volltext http://www.mitpressjournals.org/doi/abs/10.1162/POSC_a_00160 GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHI SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-BBI GBV_ILN_11 GBV_ILN_40 GBV_ILN_105 GBV_ILN_179 GBV_ILN_702 GBV_ILN_2006 GBV_ILN_4027 GBV_ILN_4125 GBV_ILN_4193 AR 23 2015 1 80-105 |
| language |
English |
| source |
Enthalten in Perspectives on science 23(2015), 1, Seite 80-105 volume:23 year:2015 number:1 pages:80-105 |
| sourceStr |
Enthalten in Perspectives on science 23(2015), 1, Seite 80-105 volume:23 year:2015 number:1 pages:80-105 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Genetic research Management Intellectual property Intellectual property law |
| dewey-raw |
050 |
| isfreeaccess_bool |
false |
| container_title |
Perspectives on science |
| authorswithroles_txt_mv |
Myles W. Jackson @@aut@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
171174844 |
| dewey-sort |
250 |
| id |
OLC1959670220 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">OLC1959670220</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230714151817.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">160206s2015 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1162/POSC_a_00160</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">PQ20160617</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC1959670220</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVOLC1959670220</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PRQ)c1211-4f8500efa0b228c425be5ea5eb45317943fc8a525f9f40617bac59f5b757a2d20</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(KEY)0227781620150000023000100080howgenepatentsarechallengingintellectualpropertyla</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">050</subfield><subfield code="q">ZDB</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Myles W. Jackson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genetic research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Management</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intellectual property</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intellectual property law</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Perspectives on science</subfield><subfield code="d">Cambridge, Mass. : MIT Press, 1993</subfield><subfield code="g">23(2015), 1, Seite 80-105</subfield><subfield code="w">(DE-627)171174844</subfield><subfield code="w">(DE-600)1161190-X</subfield><subfield code="w">(DE-576)046617116</subfield><subfield code="x">1063-6145</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:80-105</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://dx.doi.org/10.1162/POSC_a_00160</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">http://www.mitpressjournals.org/doi/abs/10.1162/POSC_a_00160</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHI</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-TGE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-BBI</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_179</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4193</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">80-105</subfield></datafield></record></collection>
|
| author |
Myles W. Jackson |
| spellingShingle |
Myles W. Jackson ddc 050 misc Genetic research misc Management misc Intellectual property misc Intellectual property law How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent |
| authorStr |
Myles W. Jackson |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)171174844 |
| format |
Article |
| dewey-ones |
050 - General serial publications |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
OLC |
| remote_str |
false |
| illustrated |
Not Illustrated |
| issn |
1063-6145 |
| topic_title |
050 ZDB How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent Genetic research Management Intellectual property Intellectual property law |
| topic |
ddc 050 misc Genetic research misc Management misc Intellectual property misc Intellectual property law |
| topic_unstemmed |
ddc 050 misc Genetic research misc Management misc Intellectual property misc Intellectual property law |
| topic_browse |
ddc 050 misc Genetic research misc Management misc Intellectual property misc Intellectual property law |
| format_facet |
Aufsätze Gedruckte Aufsätze |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
nc |
| hierarchy_parent_title |
Perspectives on science |
| hierarchy_parent_id |
171174844 |
| dewey-tens |
050 - Magazines, journals & serials |
| hierarchy_top_title |
Perspectives on science |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)171174844 (DE-600)1161190-X (DE-576)046617116 |
| title |
How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent |
| ctrlnum |
(DE-627)OLC1959670220 (DE-599)GBVOLC1959670220 (PRQ)c1211-4f8500efa0b228c425be5ea5eb45317943fc8a525f9f40617bac59f5b757a2d20 (KEY)0227781620150000023000100080howgenepatentsarechallengingintellectualpropertyla |
| title_full |
How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent |
| author_sort |
Myles W. Jackson |
| journal |
Perspectives on science |
| journalStr |
Perspectives on science |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
000 - Computer science, information & general works |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
txt |
| container_start_page |
80 |
| author_browse |
Myles W. Jackson |
| container_volume |
23 |
| class |
050 ZDB |
| format_se |
Aufsätze |
| author-letter |
Myles W. Jackson |
| doi_str_mv |
10.1162/POSC_a_00160 |
| dewey-full |
050 |
| title_sort |
how gene patents are challenging intellectual property law: the history of the ccr5 gene patent |
| title_auth |
How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent |
| abstract |
During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market. |
| abstractGer |
During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market. |
| abstract_unstemmed |
During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_OLC SSG-OLC-PHI SSG-OLC-TGE SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-BBI GBV_ILN_11 GBV_ILN_40 GBV_ILN_105 GBV_ILN_179 GBV_ILN_702 GBV_ILN_2006 GBV_ILN_4027 GBV_ILN_4125 GBV_ILN_4193 |
| container_issue |
1 |
| title_short |
How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent |
| url |
http://dx.doi.org/10.1162/POSC_a_00160 http://www.mitpressjournals.org/doi/abs/10.1162/POSC_a_00160 |
| remote_bool |
false |
| ppnlink |
171174844 |
| mediatype_str_mv |
n |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1162/POSC_a_00160 |
| up_date |
2024-07-03T18:21:03.925Z |
| _version_ |
1803583083174166528 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">OLC1959670220</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230714151817.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">160206s2015 xx ||||| 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1162/POSC_a_00160</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">PQ20160617</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC1959670220</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVOLC1959670220</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PRQ)c1211-4f8500efa0b228c425be5ea5eb45317943fc8a525f9f40617bac59f5b757a2d20</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(KEY)0227781620150000023000100080howgenepatentsarechallengingintellectualpropertyla</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">050</subfield><subfield code="q">ZDB</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Myles W. Jackson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">How Gene Patents are Challenging Intellectual Property Law: The History of the CCR5 Gene Patent</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">During the 1980s and 90s, various branches of the federal government did their best to encourage patenting in general, and genes in particular (Rai 1999, pp. 77–109; Dutfield 2009). The United States Patent and Trademark Office (USPTO) and the Court of Appeals of the Federal Circuit (CAFC) have ceded much ground (some might argue too much ground) to the interests of the biotech industry, including Big Pharma and DNA sequencing companies. In a concerted effort to bolster this economic sector a number of curious and indeed alarming decisions have been made. This essay details the story of the interesting decision of the USPTO to grant a patent on a gene, despite the fact the patent holder listed the incorrect sequence in the specification and did not know the most relevant attribute of the gene product, namely that it was a chemokine receptor- CCR5, 1 which is the co-receptor recognized by HIV-1, the virus responsible for AIDS. We live in an age that some science-technology-and-society (STS) scholars have labeled biocapitalism (for an excellent summary of biocapitalism, see Helmreich 2008). Biological entities and processes are commodities, which have their values set by the market.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genetic research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Management</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intellectual property</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intellectual property law</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Perspectives on science</subfield><subfield code="d">Cambridge, Mass. : MIT Press, 1993</subfield><subfield code="g">23(2015), 1, Seite 80-105</subfield><subfield code="w">(DE-627)171174844</subfield><subfield code="w">(DE-600)1161190-X</subfield><subfield code="w">(DE-576)046617116</subfield><subfield code="x">1063-6145</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:80-105</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://dx.doi.org/10.1162/POSC_a_00160</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">http://www.mitpressjournals.org/doi/abs/10.1162/POSC_a_00160</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHI</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-TGE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-BBI</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_179</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4193</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="h">80-105</subfield></datafield></record></collection>
|
| score |
7.4008055 |